Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WVE-210201 single-ascending-dose placebo-controlled study in Duchenne muscular dystrophy
NL-OMON46461Phase 1Active, not recruiting
- Sponsor
- Wave Life Sciences
- Start
- Nov 2018
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing WVE-210201 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Nov 2018; status: active, not recruiting.
02
Drugs
Suvodirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON46461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46461.